BD
BD is a publicly traded global medical technology company that develops and sells medical devices, drug delivery systems, and connected care platforms serving hospital systems, pharmaceutical companies, and diagnostic laboratories across nearly 200 countries. Following the February 2026 Waters spin-off, BD operates as a focused MedTech entity.
- Company typePublic
- Founded1897
- HeadquartersFranklin Lakes, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What BD does
BD (Becton, Dickinson and Company), founded in 1897 and headquartered in Franklin Lakes, New Jersey, is a publicly traded (NYSE: BDX) global medical technology company operating as a focused MedTech entity following the February 2026 spin-off of its Biosciences & Diagnostic Solutions business to Waters Corporation. The company develops, manufactures, and sells medical devices, consumables, and connected care platforms serving hospital systems, ambulatory surgery centers, pharmaceutical companies, diagnostic laboratories, and home healthcare settings. BD produces approximately 35 billion medical devices annually and operates through direct enterprise field sales across nearly 200 countries with a workforce of 75,000-77,000 spanning 62 countries.
The company's product architecture is organized around integrated platforms: BD Pyxis automated medication dispensing and BD Alaris infusion systems are linked through the BD Incada AI analytics platform, enabling closed-loop pharmacy-to-bedside medication management with predictive deterioration alerts and natural-language inventory queries. Additional platforms include BD Kiestra laboratory automation, BD BACTEC and BD Phoenix microbiology systems, BD Vacutainer specimen collection, BD SurePath and BD Onclarity diagnostics, ChloraPrep skin antisepsis, PhaSeal hazardous drug containment, and the BD Neopak prefillable syringe and BD Libertas wearable injector drug delivery platforms for biologics. Product launches in 2026 include the Elyra Thulium Fiber Laser, Liverty TIPS and Revello vascular stents, Surgiphor 1000mL antimicrobial irrigation system, HemoSphere Stream Module, and CentroVena One central line insertion system.
Revenue is generated through a mix of medical device and consumable hardware sales, recurring consumables and service contracts tied to the installed base of dispensing, infusion, and diagnostic instruments, and pharmaceutical partnership/licensing arrangements for drug delivery combination products. Pricing is negotiated through enterprise contracts with healthcare systems on annual billing cycles, with volume-based terms varying by product, configuration, and term length. Pre-spin LTM revenue was approximately $22.2 billion with Q1 FY2026 revenue of $5.252 billion (up 1.6% reported). Strategic capital allocation post-Waters transaction includes $2 billion for accelerated share repurchases and $2 billion for debt repayment, alongside reinvestment into GLP-1 prefillable syringe capacity and AI-enabled platform expansion.
BD firmographics
Firmographics- Name
- BD
- Legal name
- Becton, Dickinson and Company
- Website
- https://bd.com
- Company type
- Public
- Founded year
- 1897
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- BD is a publicly traded global medical technology company that develops and sells medical devices, drug delivery systems, and connected care platforms serving hospital systems, pharmaceutical companies, and diagnostic laboratories across nearly 200 countries. Following the February 2026 Waters spin-off, BD operates as a focused MedTech entity.
- Ownership category
- akta.pro rank
BD industry classification
Industry- Product category
- Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Medication Inventory, Procurement & Supply Chain (Pharmacy) (HLACAKAI)
- akta.pro secondary industry
- Medication Adherence, Packaging & Fulfillment Services (Blister/Unit-Dose) (HLAFALAJ)
Keywords
Where BD is headquartered
LocationHeadquarters
- HQ city
- Franklin Lakes
- HQ country
- United States
- HQ region
- North America
Offices6 records
Markets served
BD business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Medical Device and Consumable Sales: BD generates the majority of revenue through sales of medical devices, consumables, and disposable products across its portfolio including medication management systems, infusion devices, diagnostics equipment, and surgical products. Products are sold directly to healthcare providers and through distribution channels.
- Recurring Consumables and Service Revenue: Recurring revenue from consumables used with installed base of medication dispensing systems, infusion pumps, and diagnostic instruments. Service contracts and support agreements provide predictable recurring income.
- Pharmaceutical Partnership and Drug Delivery: Revenue from pharmaceutical partnerships including prefillable syringes, wearable injectors, and combination products for biologic drug delivery. Partnerships with companies like Ypsomed and ten23 health for drug delivery platforms.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise healthcare contracts with volume-based pricing |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels9 records
BD product offering
Product offeringCore offering
BD develops, manufactures, and sells medical devices, reagent systems, drug delivery solutions, and laboratory/diagnostic instrumentation for hospitals, health systems, pharmacies, and life-science laboratories. The portfolio spans medication management (e.g., Pyxis Pro), infusion therapy (e.g., Alaris), surgical instrumentation, and connected diagnostic platforms, augmented by AI-enabled software (e.g., Incada AI) and recurring consumables revenue.
Product overview
BD offers a comprehensive integrated healthcare technology ecosystem spanning diagnostic platforms, medication management systems, drug delivery technologies, laboratory automation, infection prevention, and clinical analytics. The core platform includes BD Pyxis automated dispensing and BD Alaris infusion systems, connected through the BD Incada AI analytics platform to deliver predictive deterioration alerts and automated medication management insights. The portfolio includes BD Kiestra laboratory automation, BD FACSAria/FACSLyric flow cytometry and cell sorting systems, BD Rhapsody single-cell analysis, and BD BACTEC/BD Phoenix microbiology platforms. Drug delivery offerings comprise BD Neopak prefillable syringes, BD Libertas wearable injectors, and PhaSeal hazardous drug containment systems. Emerging innovations include the Elyra Thulium Fiber Laser for kidney stone care, Liverty and Revello vascular stents, Surgiphor surgical irrigation, HemoSphere hemodynamic monitoring, and surveillance platforms like MedMined and HealthSight. Integration with EMR systems through barcode interoperability enables closed-loop pharmacy-to-bedside workflows.
Differentiator
Problem solved
Functional benefit
Brands
- BD Accuri: Flow cytometry instruments and reagents
- BD Alaris
- BD FACS
- BD Horizon
- BD LSRFortessa
- BD Neopak
- BD Pyxis
- BD SurePath
- BD Veritor
- BD Rhapsody
- BD CLiC
- BD Incada
- ChloraPrep
- PleurX
- Surgiphor
- HemoSphere
- VitaWave
- Liverty TIPS Stent Graft
- Revello
- Elyra
- CentroVena
Products and services
- BD Pyxis Pro Connected medication management platform (automated dispensing cabinets and software) used by hospital pharmacies and nursing units to safely dispense, track, and reconcile medications.
- BD Alaris Infusion pump and drug delivery platform used by hospitals and clinical staff to deliver IV medications and fluids with dose-error-reduction safeguards.
- BD Incada AI AI-driven accuracy platform that supports safer, more precise medication administration processes within BD's connected medication management environment.
- BD Diagnostic and Laboratory Systems Diagnostic instruments, reagent systems, and related consumables used by clinical laboratories, blood banks, and diagnostic centers to perform in-vitro diagnostic testing.
- BD Surgical Instruments Surgical instrumentation and related devices used by hospital surgical teams and ambulatory surgery centers.
Quantifiable outcome
- Predictive alerts detecting patient deterioration up to 15 minutes in advance
- +3 more outcomes
Companies that use BD
Customer profileNamed customers2 records
Segments5 records
Ideal customer profiles3 records
BD technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature9 records
BD partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered minor, core and flagship.
- EnvetecminorFeasibility study partnership demonstrating that polystyrene and other medical plastics can be safely disinfected and recycled into high-quality manufacturing feedstock in closed-loop system for healthcare plastics recycling.
- Wellstar Health SystemcoreStrategic AI-powered medication management partnership deploying BD Pyxis Pro dispensing technologies, Alaris Infusion Systems, and Incada AI analytics across Wellstar's Georgia hospitals. Wellstar participates on BD's Strategic Development Council to shape future product development.
- Suttons CreekminorNon-exclusive strategic collaboration to help pharmaceutical and biotech companies navigate complexity of combination product development including biologics and GLP-1 therapies. BD's ZebraSci testing services combined with Suttons Creek's development expertise.
- SintecocoreTechnological partnership providing end-to-end connected medication management solutions for European hospitals, automating transformation of manufacturer bulk medications into individually packaged unit doses with robotics.
- Waters CorporationflagshipBD completed spin-off and combination of its Biosciences & Diagnostic Solutions business with Waters Corporation in a Reverse Morris Trust transaction valued at $18.8 billion. BD received $4 billion cash ($2B for share repurchases, $2B for debt repayment) while BD shareholders received 39.2% of combined company. This strategic separation created focused MedTech company (New BD) and combined Waters BD life sciences entity.
- ten23 healthcoreManufacturing collaboration to support commercialization of BD Libertas wearable injector for subcutaneous drug delivery. Combines BD's on-body injector platform with ten23's aseptic filling and quality control services.
- YpsomedcoreExpanded partnership to develop 5.5mL version of BD Neopak XtraFlow Glass Prefillable Syringe compatible with Ypsomed's YpsoMate 5.5 autoinjector platform for large-volume subcutaneous self-injections of biologics.
- Babson DiagnosticscoreCollaboration advancing finger-prick blood collection systems delivering venous-quality diagnostic results from small capillary samples, enabling decentralized testing in pharmacies and community settings without trained phlebotomists.
Scale indicators10 records
Recent moves8 records
Expansion highlights6 records
BD competitors and assessment
Company assessmentDirect peers
- Baxter International: Baxter is a direct competitor across infusion therapy, IV pumps, medication management, surgical products, and hospital-based medical devices, providing the closest apples-to-apples comparison for BD's hospital-focused MedTech portfolio post-Waters spin-off.
- ICU Medical: ICU Medical competes directly with BD's Alaris smart-pump franchise and Plum 360 IV pumps after acquiring Smiths Medical's infusion business, with closely overlapping medication-delivery and IV-therapy customers.
- B. Braun: B. Braun is a leading global IV therapy, infusion pump, and pharmacy admixture solutions provider, directly overlapping with BD's medication management, infusion, and pharmacy automation businesses.
- Edwards Lifesciences: Edwards is a direct competitor to BD's HemoSphere hemodynamic monitoring franchise in the ICU and OR critical-care patient monitoring space, addressing overlapping clinicians and accounts.
- Teleflex: Teleflex competes directly in vascular access, interventional products, and surgical instruments—categories BD expanded via the C.R. Bard acquisition—making it a focused comparable for BD Interventional.
Broad incumbents
- Medtronic: Medtronic is a broad incumbent in medical devices with direct overlap in vascular/interventional products (acquired Covidien), patient monitoring, and hospital capital equipment, serving similar large health system customers.
- Stryker: Stryker is a broad medical device incumbent with overlapping surgical and hospital-equipment franchises and operates with comparable scale to BD across operating rooms and acute-care settings.
- Cardinal Health: Cardinal Health's medical segment distributes and develops products overlapping with BD's hospital consumables, prefilled syringes, and surgical portfolios, while also serving pharmacy customers through its broader healthcare distribution role.
- Abbott Laboratories: Abbott is a broad incumbent medical device and diagnostics company with overlapping presence in hospital-based products, infection prevention, and vascular interventions, addressing similar institutional customers.
Emerging players
- Insulet: Insulet is a focused competitor in wearable on-body injectors for subcutaneous biologic delivery, intersecting with BD's Libertas wearable injector and Neopak prefilled-syringe strategic platform for biologics.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
BD social profiles
Digital presenceBD financial estimates
Financial estimateRevenue estimate
Valuation estimate
BD leadership team
Management profileNumber of profiles
Profiles6 records
BD subsidiaries and ownership
Company hierarchySubsidiaries3 records
BD funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BD M&A and investment
M&A and investmentM&A7 records
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BD
What does BD do?
BD develops, manufactures, and sells medical devices, reagent systems, drug delivery solutions, and laboratory/diagnostic instrumentation for hospitals, health systems, pharmacies, and life-science laboratories. The portfolio spans medication management (e.g., Pyxis Pro), infusion therapy (e.g., Alaris), surgical instrumentation, and connected diagnostic platforms, augmented by AI-enabled software (e.g., Incada AI) and recurring consumables revenue.
Is BD a public or private company?
BD is a public company. It is classified as public and is currently operating.
When was BD founded?
BD was founded in 1897. It employs 5,001 to 10,000 people.
Where is BD based?
BD is headquartered in Franklin Lakes, United States, in the North America region.
How does BD make money?
Three revenue lines are on record. Medical Device and Consumable Sales are the primary driver. The others are recurring Consumables and Service Revenue and pharmaceutical Partnership and Drug Delivery.
Who are BD's main competitors?
Direct peers on record are Baxter International, ICU Medical, B. Braun, Edwards Lifesciences and Teleflex. Broad incumbents are Medtronic, Stryker, Cardinal Health and Abbott Laboratories. Insulet is listed as an emerging player.
Does BD have an API?
No public API is recorded for BD.
What industry is BD in?
BD's product category is Medical Devices. Its primary akta.pro industry code is HLACAKAI, Medication Inventory, Procurement & Supply Chain (Pharmacy), with a secondary code of HLAFALAJ, Medication Adherence, Packaging & Fulfillment Services (Blister/Unit-Dose). Its NAICS code is 339112 and its SIC code is 3841.